Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta‐analysis of randomized studies-Reference-Cited by-同舟云学术

Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta‐analysis of randomized studies

Published:2024-03-18 Issue:4 Volume:28 Page:557-571
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Nakai Kentaro¹^ORCID,Kono Keiji²,Yamada Shunsuke³^ORCID,Taniguchi Masatomo⁴,Hamano Takayuki⁵,Fukagawa Masafumi⁶^ORCID

Affiliation:

1. Division of Nephrology and Dialysis Center Japanese Red Cross Fukuoka Hospital Fukuoka Japan

2. Division of Nephrology and Kidney Center Kobe University Graduate School of Medicine Kobe Japan

3. Department of Medicine and Clinical Science, Graduate School of Medical Sciences Kyushu University Fukuoka Japan

4. Fukuoka Renal Clinic Fukuoka Japan

5. Department of Nephrology Nagoya City University Graduate School of Medicine Nagoya Japan

6. Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine Tokai University School of Medicine Isehara Japan

Abstract

AbstractIntroductionSeveral calcimimetics, other than cinacalcet, are commercially available; however, their effects on calcium and phosphate levels have not yet been fully studied. We conducted a systematic review and meta‐analysis of randomized controlled trials to evaluate the impact of calcimimetics on the management of serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis.MethodsA systematic literature search through October 2023 and a meta‐analysis were conducted on the effects of upacicalcet, etelcalcetide, evocalcet, and cinacalcet on serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis; we searched PubMed, Ovid MEDLINE, and the Cochrane Central Register of Controlled Trials, and 21 studies comprising 6371 patients undergoing dialysis were included.ResultsParticipants treated with calcimimetics had lower serum calcium and phosphate levels than placebo.ConclusionCalcimimetics significantly reduced serum calcium and phosphate levels compared to placebo in patients with secondary hyperparathyroidism undergoing dialysis, independent of therapeutic strategy or concomitant vitamin D treatment.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.14125

Reference30 articles.

1. Association of serum phosphate concentration with the incidence of intervention for peripheral artery disease in patients undergoing hemodialysis: 10-year outcomes of the Q-Cohort Study

2. Association Between Serum Phosphate Levels and Stroke Risk in Patients Undergoing Hemodialysis

3. Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder

4. Rayyan—a web and mobile app for systematic reviews

5. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials